Leukemia Mallory

Leukemia, or leukeomyelodysplasia, is a group of malignant diseases of the hematopoietic system. It represents a complex of human myeloproliferative tumor diseases - from harmless benign myelosis to an aggressive and life-threatening form, such as indolent undifferentiated leukemia. In some cases, diffuse small-cell infiltration of the bone marrow in most acute malignant leukemias and lymphomas is either completely erased or weakly expressed, and in this regard, some authors classify such neoplasms as Mallory leukemia. In our country, this form of the disease is more often called idiopathic myelofibromatous disease. According to the WHO and EOLC criteria, there are no definitive differences between them: any diagnosis should be made only after morphological verification. But the term “leukemia” has already become customary to designate this group of diseases, so it is most correct (by analogy) to use it to designate various forms of leukemia and leukemic syndromes. The diagnosis is “Mallory leukemia,” although the synonym “idiopathic myelofibromatous disease” is used by a more limited number of hematologists. In the 50s–60s. XX century It was believed that different MCS have significant clinical differences, despite the fact that they are genetically related. It was believed that the aggressiveness of the disease in this case is not a consequence of an oncogene mutation, but is caused precisely by the polymorphism of syndromic manifestations at the first stage of its development. This conclusion was justified by the lack of a clear classical etiology in “true leukemias”. The basis of the explanation was